Tag Archives: The Stem Cell Blog

Too Soon To Declare Whether Immunotherapy Can Cure Metastatic RCC – Cancer Therapy Advisor

Too Soon To Declare Whether Immunotherapy Can Cure Metastatic RCCCancer Therapy AdvisorThe treatment of metastatic renal cell carcinoma (mRCC) has undergone several major changes, with the first approval of targeted therapy in 2005 and the first approv… Continue reading

The first gene therapy approved to treat blindness has a price tag of $850000 – Business Insider

Business InsiderThe first gene therapy approved to treat blindness has a price tag of $850000Business InsiderThe first gene therapy in the U.S., approved last month to treat a rare, inherited form of blindness, now has a price tag: $850,000. That makes… Continue reading

Geovax Labs, Inc. (GOVX) Announces Collaboration with Vaxeal on Cancer Immunotherapy Program – StreetInsider.com

Geovax Labs, Inc. (GOVX) Announces Collaboration with Vaxeal on Cancer Immunotherapy Program StreetInsider.com GeoVax Labs, Inc. (GOVX) announced today that it is collaborating with Vaxeal Holding SA on the expansion of GeoVax’s cancer immunotherapy program. GeoVax’s immuno-oncology program is based on its Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP … GeoVax to Present During China Showcase at Biotech Showcase 2018Markets Insider all 2 news articles »

GeoVax and Vaxeal to Collaborate on Cancer Immunotherapy Program GlobeNewswire (press release) ATLANTA, GA, Jan. 03, 2018 (GLOBE NEWSWIRE) — GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with Vaxeal Holding SA on the expansion of GeoVax’s cancer immunotherapy program … and more »

Zacks.com

Inovio Amends Chinese Deal for Immunotherapy, Shares Up Zacks.com Per the amended agreement, ApolloBio will have the exclusive right to develop and commercialize Inovio’s DNA immunotherapy product, VGX-3100, within Greater China (China, Hong Kong, Macao, Taiwan). Currently, VGX-3100, which is an investigational … Inovio grabs $23M through HPV immunotherapy licensing deal with China’s ApolloBioFiercePharma Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in …Markets Insider Could Inovio Pharmaceuticals, Inc. (INO) Rise Even More? The Stock Had Another Big Increase TodayFrisco Fastball Market Exclusive all 50 news articles »

HamiltonNews

Juravinski hospital offers new approach for stem cell transplants HamiltonNews It’s an approach aimed at enabling more stem cell transplant patients to stay at home rather in the hospital. Since last fall, the Juravinski Hospital and Cancer Centre (JHCC) has been treating autologous stem cell recipients who have had low doses of …

FiercePharma

Inovio grabs $23M through HPV immunotherapy licensing deal with China’s ApolloBio FiercePharma China’s ApolloBio increased its upfront payment to obtain Greater China rights to Inovio’s HPV immunotherapy. Share Facebook Twitter LinkedIn Email Print. Inovio and China’s ApolloBio have agreed to tweak their exclusive licensing deal formed about a … Inovio Amends Chinese Deal for Immunotherapy, Shares UpZacks.com Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in …Markets Insider Inovio revamps China deal; nets $23M upfront paymentPhiladelphia Business Journal Frisco Fastball all 40 news articles »

Washington Post

Gene therapy for inherited blindness sets precedent: $850000 price tag Washington Post A landmark gene therapy to treat a rare, inherited form of blindness will cost $850,000 — a price tag so daunting that its maker will offer health insurers partial rebates if the drug doesn’t work and is seeking to pilot an installment payment option … Spark Therapeutics Sets Price Of Blindness-Curing Gene Therapy At $850000Forbes A US drugmaker offers to cure rare blindness for $850000CNBC Price Tag on Gene Therapy for Rare Form of Blindness: $850KU.S. News & World Report STAT –Endpoints News all 23 news articles »